(Q40401155)

20 September 2017

1 reference

title

A risk-benefit assessment of risperidone in schizophrenia (English)

1 reference

20 September 2017

1 reference

1 reference

V A Curtis

1

1 reference

PubMed ID

7539272

20 September 2017

R W Kerwin

series ordinal

2

1 reference

20 September 2017

1 February 1995

1 reference

20 September 2017

1 reference

20 September 2017

12

1 reference

20 September 2017

2

1 reference

20 September 2017

139-145

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199512020-00006

20 September 2017

0 references

cites work

Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients

1 reference

12 December 2020

Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

1 reference

12 December 2020

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

12 December 2020

Overdose of risperidone.

1 reference

12 December 2020

Risperidone in the treatment of schizophrenia

1 reference

12 December 2020

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

1 reference

12 December 2020

Biochemical profile of risperidone, a new antipsychotic

1 reference

12 December 2020

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

12 December 2020

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

1 reference

12 December 2020

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

12 December 2020

Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial

1 reference

12 December 2020

Risperidone: clinical safety and efficacy in schizophrenia

1 reference

12 December 2020

5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.

1 reference

12 December 2020

The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study.

1 reference

12 December 2020

Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

12 December 2020

10.2165/00002018-199512020-00006

Identifiers

DOI

1 reference

PubMed ID

7539272

Dimensions Publication ID

20 September 2017

0 references

1 reference

PubMed ID

7539272